Clinical trials - HealthQuill

The US Food and Drug Administration has rejected the biotechnology company Aldeyra Therapeutics Inc’s investigational drug for treating dry eyes, over concerns with the data from the trial.

Aldeyra Therapeutics’ dry eye treatment rejected by USFDA

HQ Team April 3, 2025: The US Food and Drug Administration has rejected the biotechnology company Aldeyra Therapeutics Inc’s investigational drug for treating.

by HealthQuill
April 3, 2025
0 Comments

Grey matter in the human brain may be linked to the start of adolescent smoking and nicotine addiction — a study that may have implications for prevention and treatment.

Health Research

MIT’s 40Hz gamma stimulation shows promise in slowing Alzheimer’s progression

HQ Team March 15, 2025: A decade of research at MIT’s Picower Institute for Learning and Memory has brought hope to millions battling.

by HealthQuill
March 15, 2025
0 Comments

Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.

Health Research

Aspirin shows promise in preventing cancer metastasis

HQ Team March 10, 2025: University of Cambridge scientists have uncovered the mechanism behind how aspirin could reduce the spread of certain cancers.

by HealthQuill
March 10, 2025
0 Comments

AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.

Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

by HealthQuill
March 4, 2025
0 Comments

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the Anglo-Swedish company.

Drugs Health Pharma

AstraZeneca says trial breast cancer drug improves survival rates

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the.

by HealthQuill
February 26, 2025
0 Comments

FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.

Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

by HealthQuill
February 21, 2025
0 Comments

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish drugmaker.

Uncategorized

EU panel gives a positive opinion for AstraZeneca’s cancer drug

AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.

by HealthQuill
February 3, 2025
0 Comments

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according to a company statement.

Drugs Health Medical

Merck & Co stops final-stage drug trial for treating PAH

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.